Resection of residual tumor tissue during tumor surgery has always been a medical problem, seriously affecting patient prognosis and medical resources. To solve this problem, a research team from the University of Michigan and the University of California, San Francisco, developed the artificial intelligence diagnostic tool FastGlioma, which can identify and remove brain tumors in real time during surgery, significantly improving surgical efficiency and accuracy. Downcodes editors will take you through the details of this breakthrough technology.
Picture source note: The picture is generated by AI, and the picture authorization service provider Midjourney
During surgery, if a patient suspects diffuse glioma, the surgeon will sample tissue from the surgical margins. Using the portable SRH imaging system, technicians can quickly acquire microscope images in the operating room through simple touch screen operations. Fresh surgical specimens are placed directly into custom microscope slides, eliminating the need for tedious tissue handling.
The FastGlioma system uses advanced stimulated Raman histology technology to enable rapid and high-resolution analysis of fresh, unprocessed surgical specimens. According to research, FastGlioma can identify residual tumor tissue in just 10 seconds with an accuracy of up to 92%, far exceeding traditional imaging and fluorescence detection methods. Compared with traditional methods, which miss up to 25% of residual tumors, FastGlioma reduces the missed detection rate to only 3.8%. This significant improvement heralds improved surgical outcomes and improved patient survival.
In addition, the underlying technology of FastGlioma is derived from vision-based models like GPT-4 and DALL-E. These models have been trained on more than 11,000 surgical specimens and 4 million unique microscope fields, and can adapt to different patient groups and medical treatments. environment. The system's user-friendly interface allows surgeons to obtain immediate and actionable insights during operations, improving decision-making efficiency.
FastGlioma's potential is not limited to gliomas, and the researchers believe the technology could be expanded to other types of brain tumors. In the future, the team hopes to promote FastGlioma to the fields of lung cancer, prostate cancer, breast cancer, and head and neck cancer. If successful, it may usher in a new era of surgical oncology.
The emergence of FastGlioma has brought new hope to tumor surgery. Its high accuracy and rapid diagnostic capabilities are expected to significantly improve patient prognosis and bring revolutionary changes to the field of surgical oncology. In the future, we expect this technology to benefit more patients and benefit all mankind.